Cross-license deal will combine their technologies.
U.S.-based NanoBioMagnetics and U.K.-based nanoTherics entered into a global cross-license agreement that enhances their businesses outside their respective geographies. The companies both use magnetically responsive nanoparticles for life science research, diagnostics, and delivery systems.
The firms’ respective technologies are synergistic. nanoTherics exploits a gene transfection technology that uses nanoparticles and magnetic fields to facilitate delivery of foreign molecules including DNA into living cells. Its magnefect-nano™ gene transfection device shows significant performance enhancement over the best nonviral transfection techniques currently on the market and demonstrates high levels of transfection while maintaining viability of transfected cells, according to nanoTherics.
NanoBioMagnetics focuses on organ-assisting devices, which employ magnetically responsive nanoparticles to cause or drive a desired physiological event when activated by an external magnetic field.